Intercept Somatic


About this study

The goal of this study is to assess the diagnostic yield of concomitant germline and somatic tumor profile testing in a population of cancer patients unselected for family cancer history. In this study, we will retrospectively perform TMP on all cancer patients enrolled into the IRB 18-00326 who underwent germline genetic testing and have tumor tissue available within the Mayo Clinic Tissue Archives. TMP will be performed using a 435 gene platform, along with assessment of tumor mutational burden and microsatellite instability status, among other analyses. Paraffin-embedded tissues will be obtained from the Mayo Tissue Registry and will be shipped to Invitae (San Francisco) for the above TMP analysis. No patient identifiers will be shared with the team at Invitae. Somatic mutation analysis by next-generation sequencing (NGS) is an expanding clinical assessment being offered to cancer patients and we hypothesize will have implications for the patient’s acute treatment, ongoing surveillance, and the screening of family members.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Niloy Jewel Samadder, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer